ID

24611

Descripción

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00509769

Link

https://clinicaltrials.gov/show/NCT00509769

Palabras clave

Versiones (1)
  1. 8/8/17 8/8/17 -
Subido en

8 de agosto de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Metastatic Breast Cancer NCT00509769

Inglés

Eligibility Metastatic Breast Cancer NCT00509769

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
signed informed consent form.
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
human epidermal growth factor receptor 2 (her2)-positive metastatic breast cancer (mbc); tissue (slides or blocks) available for her2 confirmation.
Descripción

Secondary malignant neoplasm of female breast HER2/Neu Positive | Tissue specimen Available

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0346993
UMLS CUI [1,2]
C2348909
UMLS CUI [2,1]
C1292533
UMLS CUI [2,2]
C0470187
history of progression on her2-directed therapy for the treatment of her2-positive breast cancer.
Descripción

Therapeutic procedure HER2 Targeted HER2-positive carcinoma of breast

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0069515
UMLS CUI [1,3]
C1521840
UMLS CUI [1,4]
C1960398
at least 1, and no more than 3, chemotherapy regimens for mbc.
Descripción

Chemotherapy Regimen Quantity Secondary malignant neoplasm of female breast

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0346993
granulocyte count ≥ 1500/μl, platelet count ≥ 100,000/μl, and hemoglobin ≥ 9 g/dl.
Descripción

Granulocyte count | Platelet Count measurement | Hemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0857490
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0518015
serum bilirubin ≤ 1.5 mg/dl, aspartate aminotransferase (ast), alanine aminotransferase (alt), and alkaline phosphatase ≤ 2.5x the upper limit of normal (uln).
Descripción

Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0201836
UMLS CUI [4]
C0201850
serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min.
Descripción

Creatinine measurement, serum | Creatinine clearance measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0373595
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biological therapy for the treatment of breast cancer within 2 weeks of the first study treatment.
Descripción

Chemotherapy Breast Carcinoma | Hormone Therapy Breast Carcinoma | Therapeutic radiology procedure Breast Carcinoma | Immunotherapy Breast Carcinoma | Biological treatment Breast Carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0678222
UMLS CUI [2,1]
C0279025
UMLS CUI [2,2]
C0678222
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C0678222
UMLS CUI [4,1]
C0021083
UMLS CUI [4,2]
C0678222
UMLS CUI [5,1]
C1531518
UMLS CUI [5,2]
C0678222
prior cumulative doxorubicin dose > 360 mg/m^2 or the equivalent.
Descripción

Doxorubicin Cumulative Dose

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013089
UMLS CUI [1,2]
C2986497
history of significant cardiac disease, unstable angina, congestive heart failure (chf), myocardial infarction, or ventricular arrythmia requiring medication.
Descripción

Heart Diseases | Angina, Unstable | Congestive heart failure | Myocardial Infarction | Ventricular arrhythmia Requirement Pharmaceutical Preparations

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0002965
UMLS CUI [3]
C0018802
UMLS CUI [4]
C0027051
UMLS CUI [5,1]
C0085612
UMLS CUI [5,2]
C1514873
UMLS CUI [5,3]
C0013227
Volver a la parte superior de la página

Similar models

Eligibility Metastatic Breast Cancer NCT00509769

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
signed informed consent form.
boolean
C0021430 (UMLS CUI [1])
Secondary malignant neoplasm of female breast HER2/Neu Positive | Tissue specimen Available
Item
human epidermal growth factor receptor 2 (her2)-positive metastatic breast cancer (mbc); tissue (slides or blocks) available for her2 confirmation.
boolean
C0346993 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C1292533 (UMLS CUI [2,1])
C0470187 (UMLS CUI [2,2])
Therapeutic procedure HER2 Targeted HER2-positive carcinoma of breast
Item
history of progression on her2-directed therapy for the treatment of her2-positive breast cancer.
boolean
C0087111 (UMLS CUI [1,1])
C0069515 (UMLS CUI [1,2])
C1521840 (UMLS CUI [1,3])
C1960398 (UMLS CUI [1,4])
Chemotherapy Regimen Quantity Secondary malignant neoplasm of female breast
Item
at least 1, and no more than 3, chemotherapy regimens for mbc.
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
Granulocyte count | Platelet Count measurement | Hemoglobin measurement
Item
granulocyte count ≥ 1500/μl, platelet count ≥ 100,000/μl, and hemoglobin ≥ 9 g/dl.
boolean
C0857490 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement
Item
serum bilirubin ≤ 1.5 mg/dl, aspartate aminotransferase (ast), alanine aminotransferase (alt), and alkaline phosphatase ≤ 2.5x the upper limit of normal (uln).
boolean
C1278039 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201850 (UMLS CUI [4])
Creatinine measurement, serum | Creatinine clearance measurement
Item
serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min.
boolean
C0201976 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Chemotherapy Breast Carcinoma | Hormone Therapy Breast Carcinoma | Therapeutic radiology procedure Breast Carcinoma | Immunotherapy Breast Carcinoma | Biological treatment Breast Carcinoma
Item
any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biological therapy for the treatment of breast cancer within 2 weeks of the first study treatment.
boolean
C0392920 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C1522449 (UMLS CUI [3,1])
C0678222 (UMLS CUI [3,2])
C0021083 (UMLS CUI [4,1])
C0678222 (UMLS CUI [4,2])
C1531518 (UMLS CUI [5,1])
C0678222 (UMLS CUI [5,2])
Doxorubicin Cumulative Dose
Item
prior cumulative doxorubicin dose > 360 mg/m^2 or the equivalent.
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
Heart Diseases | Angina, Unstable | Congestive heart failure | Myocardial Infarction | Ventricular arrhythmia Requirement Pharmaceutical Preparations
Item
history of significant cardiac disease, unstable angina, congestive heart failure (chf), myocardial infarction, or ventricular arrythmia requiring medication.
boolean
C0018799 (UMLS CUI [1])
C0002965 (UMLS CUI [2])
C0018802 (UMLS CUI [3])
C0027051 (UMLS CUI [4])
C0085612 (UMLS CUI [5,1])
C1514873 (UMLS CUI [5,2])
C0013227 (UMLS CUI [5,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial